TENX ▼ -1.4% - Tenax Therapeutics, Inc. $TENX - Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 Tenax Therapeutics shares declined 1.4% today following the company's announcement of a Phase 3 LEVEL trial presentation at the upcoming ESC Congress 2026. While the presentation of late-breaking clinical results typically represents a significant milestone for a biotech company, the market's muted negative response suggests investors may have been expecting more substantial data or news at this time, or the stock may have already priced in positive expectations ahead of the announcement. 29-AUG-2026 08:21 AM ET